BetterLife Pharma Inc.
BETR
CNSX
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 517.80K | 614.00K | 1.59M | 403.10K | 416.10K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 523.20K | 811.40K | 1.67M | 540.90K | 514.50K |
| Operating Income | -523.20K | -811.40K | -1.67M | -540.90K | -514.50K |
| Income Before Tax | 470.80K | -1.06M | -1.51M | -513.70K | -157.40K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 470.80K | -1.06M | -1.51M | -513.70K | -157.40K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -30.10K | 6.40K | 75.50K | -451.10K | 13.50K |
| Net Income | 440.60K | -1.05M | -1.43M | -964.80K | -143.90K |
| EBIT | -523.20K | -811.40K | -1.67M | -540.90K | -514.50K |
| EBITDA | -- | -- | -- | -537.50K | -511.10K |
| EPS Basic | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 |
| Normalized Basic EPS | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 |
| EPS Diluted | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 |
| Normalized Diluted EPS | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 |
| Average Basic Shares Outstanding | 129.46M | 120.45M | 115.90M | 114.91M | 112.84M |
| Average Diluted Shares Outstanding | 146.76M | 120.45M | 115.90M | 114.91M | 112.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
